G. Remuzzi, C. Chiurchiu, M. Abbate, V. Brusegan, M. Bontempelli et al., Rituximab for idiopathic membranous nephropathy, Lancet, vol.360, pp.923-924, 2002.

A. S. Bomback, V. K. Derebail, J. G. Mcgregor, A. V. Kshirsagar, R. J. Falk et al., Rituximab therapy for membranous nephropathy: A systematic review, Clin J Am Soc Nephrol, vol.4, pp.734-744, 2009.

P. Cravedi, M. C. Sghirlanzoni, M. Marasà, A. Salerno, G. Remuzzi et al., Efficacy and safety of rituximab second-line therapy for membranous nephropathy: A prospective, matched-cohort study, Am J Nephrol, vol.33, pp.461-468, 2011.

A. Segarra, M. Praga, N. Ramos, N. Polanco, I. Cargol et al., Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients, Clin J Am Soc Nephrol, vol.4, pp.1083-1088, 2009.

P. Ruggenenti, P. Cravedi, A. Chianca, A. Perna, B. Ruggiero et al., Rituximab in idiopathic membranous nephropathy, J Am Soc Nephrol, vol.23, pp.1416-1425, 2012.

R. J. Glassock, Human idiopathic membranous nephropathy-a mystery solved?, N Engl J Med, vol.361, pp.81-83, 2009.

P. Ruggenenti, P. Cravedi, and G. Remuzzi, Latest treatment strategies for membranous nephropathy, Expert Opin Pharmacother, vol.8, pp.3159-3171, 2007.

H. Debiec, V. Guigonis, B. Mougenot, F. Decobert, J. P. Haymann et al., Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies, N Engl J Med, vol.346, pp.2053-2060, 2002.

L. H. Beck, R. G. Bonegio, G. Lambeau, D. M. Beck, D. W. Powell et al., M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy, N Engl J Med, vol.361, pp.11-21, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00417718

, J Am Soc Nephrol, vol.26, pp.2545-2558, 2015.

P. Cravedi, P. Ruggenenti, and G. Remuzzi, Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy, J Am Soc Nephrol, vol.22, pp.1400-1402, 2011.

H. C. Stanescu, M. Arcos-burgos, A. Medlar, D. Bockenhauer, A. Kottgen et al., Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy, N Engl J Med, vol.364, pp.616-626, 2011.

G. Bullich, J. Ballarín, A. Oliver, N. Ayasreh, I. Silva et al., HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy, Clin J Am Soc Nephrol, vol.9, pp.335-343, 2014.

J. Lv, W. Hou, X. Zhou, G. Liu, F. Zhou et al., Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy, J Am Soc Nephrol, vol.24, pp.1323-1329, 2013.

H. Debiec and P. Ronco, Immunopathogenesis of membranous nephropathy: An update, Semin Immunopathol, vol.36, pp.381-397, 2014.

P. Cravedi, P. Ruggenenti, M. C. Sghirlanzoni, and G. Remuzzi, Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy, Clin J Am Soc Nephrol, vol.2, pp.932-937, 2007.

D. Kanigicherla, J. Gummadova, E. A. Mckenzie, S. A. Roberts, S. Harris et al., Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy, Kidney Int, vol.83, pp.940-948, 2013.

E. Hoxha, I. Thiele, G. Zahner, U. Panzer, S. Harendza et al., Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy, J Am Soc Nephrol, vol.25, pp.1357-1366, 2014.

J. M. Hofstra, H. Debiec, C. D. Short, T. Pellé, R. Kleta et al., Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy, J Am Soc Nephrol, vol.23, pp.1735-1743, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00919117

J. M. Hofstra, L. H. Beck, D. M. Beck, J. F. Wetzels, and D. J. Salant, Anti-phospholipase A? receptor antibodies correlate with clinical status in idiopathic membranous nephropathy, Clin J Am Soc Nephrol, vol.6, pp.1286-1291, 2011.

L. H. Beck, F. C. Fervenza, D. M. Beck, R. G. Bonegio, F. A. Malik et al., Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy, J Am Soc Nephrol, vol.22, pp.1543-1550, 2011.

M. J. Penny, R. A. Boyd, and B. M. Hall, Mycophenolate mofetil prevents the induction of active Heymann nephritis: Association with Th2 cytokine inhibition, J Am Soc Nephrol, vol.9, pp.2272-2282, 1998.

B. Coiffier, M. Pfreundschuh, R. Stahel, J. Vose, and P. L. Zinzani, Aggressive lymphoma: Improving treatment outcome with rituximab, Anticancer Drugs, vol.13, pp.43-50, 2002.

P. Ruggenenti, B. Ruggiero, P. Cravedi, M. Vivarelli, L. Massella et al., Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group: Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome, J Am Soc Nephrol, vol.25, pp.850-863, 2014.

G. Cambridge, D. A. Isenberg, J. C. Edwards, M. J. Leandro, T. S. Migone et al., Stohl W: B cell depletion therapy in systemic lupus erythematosus: Relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response, Ann Rheum Dis, vol.67, pp.1011-1016, 2008.

Y. K. Teng, G. Wheater, V. E. Hogan, P. Stocks, E. W. Levarht et al., Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity, Arthritis Res Ther, vol.14, p.57, 2012.

F. C. Fervenza, R. S. Abraham, S. B. Erickson, M. V. Irazabal, A. Eirin et al.,

C. Mayo-nephrology and . Group, Rituximab therapy in idiopathic membranous nephropathy: A 2-year study, Clin J Am Soc Nephrol, vol.5, pp.2188-2198, 2010.

M. Fresquet, T. A. Jowitt, J. Gummadova, R. Collins, R. O'cualain et al., Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy

, J Am Soc Nephrol

S. Kim, H. J. Chin, K. Y. Na, S. Kim, J. Oh et al., PREMIER) members: Single nucleotide polymorphisms in the phospholipase A2 receptor gene are associated with genetic susceptibility to idiopathic membranous nephropathy, Progressive Renal Disease and Medical Informatics and Genomics Research, vol.117, pp.253-258, 2011.

E. Bresin, S. Gastoldi, D. E. Belotti, D. Pogliani, E. Perseghin et al., Rituximab as preemptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies, Thromb Haemost, vol.101, pp.233-238, 2009.

P. Royston and W. Sauerbrei, Multivariable model-building. A pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables, 2008.

P. Royston, W. Sauerbrei, and H. Becher, Modelling continuous exposures with a 'spike' at zero: A new procedure based on fractional polynomials, Stat Med, vol.29, pp.1219-1227, 2010.

H. Becher, E. Lorenz, P. Royston, and W. Sauerbrei, Analysing covariates with spike at zero: A modified FP procedure and conceptual issues, Biom J, vol.54, pp.686-700, 2012.

, Anti-phospholipase A 2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A 2 Receptor Autoantibodies, pp.2308-2311